Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results

LESSONS LEARNED. Despite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing. Safety was documented, although dose escalation was...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncologist
मुख्य लेखकों: O'Reilly, Eileen M., Roach, James, Miller, Paul, Yu, Kenneth H., Tjan, Catherine, Rosano, Molly, Krause, Silva, Avery, William, Wolf, Julie, Flaherty, Keith, Nix, Darrell, Ryan, David P.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: AlphaMed Press 2017
विषय:
Clinical Trial Results
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728039/
https://ncbi.nlm.nih.gov/pubmed/29158367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0472
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन